Molidustat
chemical compound
Molidustat is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.
Veterinary use
Molidustat is indicated for the control of nonregenerative anemia associated with chronic kidney disease in cats. The US Food and Drug Administration (FDA) conditionally approved it in May 2023.
The reasonable expectation of effectiveness of Molidustat was evaluated in a study conducted in two phases. The first phase involved a multi-center, double-masked, randomized, placebo-controlled field effectiveness and safety study. The second phase was an unmasked, optional continuation of the field study. The study enrolled 23 cats from 4 to 17 years of age from various breeds or breed mixes diagnosed with nonregenerative anemia associated with chronic kidney disease. The FDA granted conditional approval of Varenzin-CA1 to Elanco US Inc.
This brief starts where responsible research should: with the source description of “Molidustat” as chemical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Jul 23, 2026. The linked authority identifier is Q27087553. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2023.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Molidustat”, its source revision and the description used here.
- Expand the search: follow Molidustat primary sources, Molidustat archive and Molidustat research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Molidustat”?
- Is the terminology current, historical or disputed?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Molidustat” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.